The aims section gives detail on what the researchers wanted to find out. 

Below is an example of the aims section:
• If people with mCRC whose tumors have the BRAF V600E mutation and are MSI–H/dMMR may respond better to the combination of pembrolizumab with encorafenib plus cetuximab than to pembrolizumab alone